New shot could cut heart attacks and strokes in High-Risk patients

NCT ID NCT07551492

Recruiting now Disease control Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial is testing an injectable drug called HRS9531 in about 9,200 people with atherosclerotic cardiovascular disease (hardened arteries). The goal is to see if it can lower the chance of major heart problems like heart attack, stroke, or death. Participants receive either the drug or a placebo shot, and the study will last until enough heart events occur to compare the groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS9531 injection
What this could lead to: If it works, this could provide a new treatment to lower the risk of major heart problems like heart attack or stroke in people with hardened arteries.
What could go wrong: This is a large Phase 3 trial, but the drug is still experimental. It may not prove effective, and side effects are possible. Results are not expected for several years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis atherosclerotic cardiovascular disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATHEROSCLEROTIC CARDIOVASCULAR DISEASE

Contacts and locations

Locations

Fuwai Hospital, CAMS&PUMC
RECRUITING

Beijing, Beijing Municipality, 100037, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.